FDA Approves METHOTREXATE — Mylan Pharmaceuticals Inc.

# FDA Approval Newswire Mylan Pharmaceuticals Inc. received FDA approval for its oral methotrexate sodium formulation (ANDA081235), expanding the company's oncology and immunology portfolio with a generic entry into the competitive methotrexate market. The approval positions Mylan to capture market share in the cost-sensitive segment for this widely-used cancer and autoimmune disease treatment.